HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account

Frits Van Rhee, MD, PhD

Professor of Medicine and Director of Developmental and Translational Medicine

38 years treating Myeloma | 850 Myeloma patients treated annually

Clinical Expertise

Castleman Disease. Also an expert in multiple myeloma and other hematologic malignancies, with a research focus in immunotherapy.

About

Frits van Rhee, M.D., Ph.D., is a Professor of Medicine and Clinical Director of the UAMS Myeloma Center. He earned his medical degree from Erasmus University, Rotterdam, Netherlands, and his Ph.D. at the Imperial College of Science, Medicine and Technology, University of London. Dr. van Rhee trained in Internal Medicine and Hematology in the U.K., and in Bone Marrow Transplantation at John Radcliffe University Hospital in Oxford and the Royal Postgraduate Medical School in London. He holds the Charles and Clydene Scharlau Chair for Hematological Malignancies.

Dr. van Rhee is an international expert on Castleman Disease, with one of the largest populations of Castleman Disease patients in the world.  He also is an expert in multiple myeloma and other hematologic malignancies, with a research focus in immunotherapy.

Dr. van Rhee is a member of the International Society for Cellular Therapy, the International Society for Experimental Hematology, the European Group for Bone and Marrow Transplantation, the Royal college of Physicians (U.K.), the Royal College of Pathologists (U.K.), and the American Society of Hematology. He has U.K. board certification in Internal Medicine and Hematology.

Location

University Of Arkansas Medical Sciences: 4301 W Markham St # 816, Little Rock, AR 72205, USA

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube